Published in J Bone Miner Res on February 01, 2001
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis (2012) 4.81
Functional articular cartilage repair: here, near, or is the best approach not yet clear? Nat Rev Rheumatol (2013) 1.09
Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res (2009) 1.00
Targets, models and challenges in osteoarthritis research. Dis Model Mech (2015) 0.99
Plant and fungal food components with potential activity on the development of microbial oral diseases. J Biomed Biotechnol (2011) 0.94
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int (2012) 0.91
Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model. Acta Pharmacol Sin (2013) 0.84
Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence. Ther Adv Musculoskelet Dis (2013) 0.83
Meniscal extrusion promotes knee osteoarthritis structural progression: protective effect of strontium ranelate treatment in a phase III clinical trial. Arthritis Res Ther (2015) 0.80
Small-molecule based musculoskeletal regenerative engineering. Trends Biotechnol (2014) 0.80
Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. Acta Pharmacol Sin (2012) 0.79
Strontium mineralization of shark vertebrae. Sci Rep (2016) 0.79
Repairing defect and preventing collapse of femoral head in a steroid-induced osteonecrotic of femoral head animal model using strontium-doped calcium polyphosphate combined BM-MNCs. J Mater Sci Mater Med (2015) 0.77
Impact of treatments for osteoporosis on cartilage biomarkers in humans. Osteoporos Int (2012) 0.76
The morphology and lattice structure of bone crystal after strontium treatment in goats. J Bone Miner Metab (2009) 0.76
Strontium ranelate causes osteophytes overgrowth in a model of early phase osteoarthritis. BMC Musculoskelet Disord (2017) 0.75
Strontium ranelate stimulates trabecular bone formation in a rat tibial bone defect healing process. Osteoporos Int (2017) 0.75
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
A simple tool to identify asian women at increased risk of osteoporosis. Osteoporos Int (2001) 2.06
Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA (2001) 1.72
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int (2008) 1.65
An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res (1993) 1.60
Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int (2012) 1.58
Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab (2002) 1.57
Nitric oxide downregulates interleukin 1beta (IL-1beta) stimulated IL-6, IL-8, and prostaglandin E2 production by human chondrocytes. J Rheumatol (1998) 1.55
Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res (1996) 1.48
Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporos Int (1997) 1.43
Rheumatic and musculoskeletal diseases and impaired quality of life: a challenge for rheumatologists. J Rheumatol (1996) 1.42
Incorporation and distribution of strontium in bone. Bone (2001) 1.40
[Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate]. Gynecol Obstet Fertil (2003) 1.40
The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone (1996) 1.38
Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage (2007) 1.26
Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone (2001) 1.22
A comparison of voluntary and electrically induced contractions by interleaved 1H- and 31P-NMRS in humans. J Appl Physiol (1985) (2002) 1.22
Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev (2006) 1.19
Non-pore lining amino acid side chains influence anion selectivity of the human CFTR Cl- channel expressed in mammalian cell lines. J Physiol (1998) 1.19
Social support and health-related quality of life in hip and knee osteoarthritis. Qual Life Res (2004) 1.17
Phalangeal osteosonogrammetry study: age-related changes, diagnostic sensitivity, and discrimination power. The Phalangeal Osteosonogrammetry Study Group. J Bone Miner Res (2000) 1.13
Adherence to treatment of osteoporosis: a need for study. Osteoporos Int (2007) 1.13
Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int (2009) 1.13
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab (2000) 1.10
S 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res (2003) 1.09
Phenotypic characterization of osteoblasts from the sclerotic zones of osteoarthritic subchondral bone. Arthritis Rheum (2008) 1.09
Tools in the assessment of sarcopenia. Calcif Tissue Int (2013) 1.09
Bone mineral content and physical activity. Int J Sports Med (1987) 1.09
The role of calcium and vitamin D in the management of osteoporosis. Bone (2007) 1.06
Interleukin-1beta and interleukin-6 disturb the antioxidant enzyme system in bovine chondrocytes: a possible explanation for oxidative stress generation. Osteoarthritis Cartilage (2008) 1.06
WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.06
Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol (2004) 1.05
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int (2012) 1.05
Effects of training on exercise-induced muscle damage and interleukin 6 production. Muscle Nerve (1999) 1.05
Effects of exogenous IL-1 beta, TNF alpha, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthritis Cartilage (1996) 1.02
S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone (2003) 1.00
Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas (1997) 1.00
Reactive oxygen species downregulate the expression of pro-inflammatory genes by human chondrocytes. Inflamm Res (2003) 1.00
Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporos Int (2007) 0.99
Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry. Gynecol Endocrinol (2002) 0.99
Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers. Osteoarthritis Cartilage (2001) 0.99
Paget's disease of bone: diagnosis and management. BMJ (1996) 0.98
Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis. Calcif Tissue Int (1995) 0.97
On conducting burden-of-osteoporosis studies: a review of the core concepts and practical issues. A study carried out under the auspices of a WHO Collaborating Center. Rheumatology (Oxford) (2001) 0.96
One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis (2007) 0.96
Myocellular enzyme leakage, polymorphonuclear neutrophil activation and delayed onset muscle soreness induced by isokinetic eccentric exercise. Arch Physiol Biochem (1996) 0.96
Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. Rheumatol Int (2006) 0.96
Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporos Int (2013) 0.95
Strontium increases vertebral bone volume in rats at a low dose that does not induce detectable mineralization defect. Bone (1996) 0.95
Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int (2012) 0.95
Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol (2001) 0.94
European regulatory perspectives for innovative therapies. Osteoporos Int (2008) 0.93
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int (1998) 0.92
Comparison between bone density and bone strength in glucocorticoid-treated aged ewes. Bone (1995) 0.92
Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels. Aging Clin Exp Res (2002) 0.92
Intensive and prolonged health promotion strategy may increase awareness of osteoporosis among postmenopausal women. Osteoporos Int (2001) 0.91
Energy expenditure of ambulation in paraplegics: effects of long term use of bracing. Paraplegia (1984) 0.91
Genetic markers of osteoarticular disorders: facts and hopes. Arthritis Res (2001) 0.91
Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis (2011) 0.91
Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin Rheumatol (1998) 0.90
The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int (2002) 0.89
Shoulder function after latissimus dorsi transfer in breast reconstruction. Clin Physiol Funct Imaging (2010) 0.89
Isokinetic assessment of the shoulder rotators: a study of optimal test position. Clin Physiol Funct Imaging (2011) 0.89
Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in a sample of white women from Belgium. Bone (2001) 0.87
Anaerobic and aerobic power of top athletes. Eur J Appl Physiol Occup Physiol (1981) 0.87
Management of osteoporosis of the oldest old. Osteoporos Int (2014) 0.87
A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int (1997) 0.87
Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int (2003) 0.87
[A FRAX model for the assessment of fracture probability in Belgium]. Rev Med Liege (2009) 0.86
The chemical biomarkers C2C, Coll2-1, and Coll2-1NO2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice. Arthritis Rheum (2007) 0.86
A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res (2001) 0.86
Effects of etodolac on human chondrocytes cultivated in three dimensional culture. Clin Rheumatol (1989) 0.86
Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum (1995) 0.85
Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev (2006) 0.85
Sciatic nerve regeneration through venous or nervous grafts in the rat. Exp Neurol (1997) 0.85
Floctafenin versus acetaminophen for pain control in patients with osteoarthritis in the lower limbs. Franco-Belgian Task Force. Rev Rhum Engl Ed (1997) 0.85
Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol (1985) 0.85
The use of different dual X-ray absorptiometry brands in a multicenter clinical trial: consequences and limits. J Clin Densitom (1999) 0.84
Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int (2012) 0.84
Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. Lancet (1999) 0.83
Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J Clin Endocrinol Metab (1999) 0.83
Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX) to assess the 10-year probability of fracture. Rheumatol Int (2012) 0.83
Fate of exogenous glucose during exercise of different intensities in humans. J Appl Physiol Respir Environ Exerc Physiol (1982) 0.83
Chronic fatigue syndrome: a systematic review. Ann Readapt Med Phys (2006) 0.83
Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthritis Cartilage (2000) 0.83
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int (2009) 0.83
Evidence that recipient CD8+ T cell depletion does not alter development of chronic vascular rejection in a rat heart allograft model. Transplantation (1994) 0.83
Fractures in osteoporosis: the challenge for the new millennium. Osteoporos Int (2005) 0.82
[Value of using Reparil-gel in sports traumatology]. Acta Belg Med Phys (1987) 0.82